Internal Medicine, Hematology & Oncology · New York, NY
NPI
1699852962
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
12 E 86th St, Ofc 4
New York, NY, 10028
Phone (212) 861-6660
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
77,561 services
Medicare patients, 2024
1,032
Average age 77
Drug cost, 2024
$7.0M
1,322 prescriptions
Company payments, 2025
$147
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amory V Novoselac was code J1439 (injection, ferric carboxymaltose, 1 mg), 25,500 times for 30 patients. In total Amory V Novoselac billed 77,561 services in 194 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-05-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 25,500 | 30 | $0.88 | $22K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 9,700 | 12 | $2.26 | $22K |
| 88185 Surgical Pathology Examination | Office | 5,645 | 191 | $22.08 | $125K |
| 36415 Venipuncture Blood Collection | Office | 1,879 | 951 | $8.64 | $16K |
| J0897 Injection, denosumab, 1 mg | Office | 1,800 | 22 | $20.26 | $36K |
| 85025 Blood Count | Office | 1,765 | 924 | $7.60 | $13K |
| 80053 Clinical Chemistry | Office | 1,620 | 882 | $10.32 | $17K |
| 99214 Office E&M - Established | Office | 1,105 | 584 | $110.77 | $122K |
| 82728 Clinical Chemistry | Office | 1,046 | 635 | $13.34 | $14K |
| 83540 Clinical Chemistry | Office | 1,045 | 632 | $6.33 | $6,614 |
| 82784 Immunoassay | Office | 853 | 221 | $9.11 | $7,774 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 771 | 159 | $52.44 | $40K |
| 83550 Clinical Chemistry | Office | 688 | 497 | $8.56 | $5,889 |
| 83615 Clinical Chemistry | Office | 614 | 469 | $5.90 | $3,624 |
| 83521 Immunoassay | Office | 609 | 237 | $16.92 | $10K |
By year: 2022 $2.5M for 229,039 services; 2023 $1.8M for 139,432 services; 2024 $1.1M for 77,561 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 5,645 | 191 | $22.08 | $125K |
| 36415 Venipuncture Blood Collection | 1,879 | 951 | $8.64 | $16K |
| 85025 Blood Count | 1,765 | 924 | $7.60 | $13K |
| 80053 Clinical Chemistry | 1,620 | 882 | $10.32 | $17K |
| 82728 Clinical Chemistry | 1,046 | 635 | $13.34 | $14K |
| 83540 Clinical Chemistry | 1,045 | 632 | $6.33 | $6,614 |
| 82784 Immunoassay | 853 | 221 | $9.11 | $7,774 |
| 83550 Clinical Chemistry | 688 | 497 | $8.56 | $5,889 |
| 83615 Clinical Chemistry | 614 | 469 | $5.90 | $3,624 |
| 83521 Immunoassay | 609 | 237 | $16.92 | $10K |
Medicare prescription drug claims, 2024
In 2024, the drug Amory V Novoselac prescribed most often to Medicare patients was Xgeva (Denosumab), with 107 prescriptions and refills. In total Amory V Novoselac wrote 1,322 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xgeva Denosumab | 107 | 107 | 15 | $342K |
| Aranesp Darbepoetin Alfa In Polysorbat | 103 | 103 | 22 | $345K |
| Eliquis Apixaban | 86 | 118 | 27 | $66K |
| Akynzeo Fosnetupitant/Palonosetron | 60 | 60 | 14 | $59K |
| Lupron Depot Leuprolide Acetate | 60 | 91 | 11 | $177K |
| Somatuline Depot Lanreotide Acetate | 43 | 43 | Under 11 | $390K |
| Xtandi Enzalutamide | 38 | 38 | Under 11 | $550K |
| Mvasi Bevacizumab-Awwb | 37 | 37 | Under 11 | $159K |
| Procrit Epoetin Alfa | 34 | 34 | 11 | $89K |
| Hydroxyurea Generic | 34 | 70 | Under 11 | $1,265 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 33 | 33 | Under 11 | $409K |
| Anastrozole Generic | 31 | 57 | Under 11 | $426 |
| Neulasta Onpro Pegfilgrastim | 31 | 31 | Under 11 | $237K |
| Revlimid Lenalidomide | 30 | 30 | Under 11 | $385K |
| Xarelto Rivaroxaban | 28 | 34 | Under 11 | $19K |
Brand drugs: 964 claims; generic drugs: - claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amory V Novoselac $147 ($147 in general payments such as food, travel and fees) from 3 companies. The largest payer was Novocure Inc. with $93.72.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.